Evaluating early inflammatory polyarthritis for better treatment outcomes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the prognostic markers in patients with early inflammatory polyarthritis, particularly focusing on rheumatoid arthritis. It seeks to identify which patients are likely to experience persistent and severe disease based on the presence of specific autoantibodies, such as anti-Sa and anti-CCP antibodies. By evaluating these markers over a period of 60 months, the study intends to improve treatment strategies by determining who should receive aggressive therapy early in their disease course. The study is conducted at the Centre hospitalier universitaire de Sherbrooke in Quebec, Canada.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Early Rheumatoid arthritis
* Early Inflammatory Arthritis

Exclusion Criteria:

* Refusal or inability to consent
* Infectious arthritis
* Microcrystalline arthritis

Where it's running

• Centre hospitalier universitaire de Sherbrooke
  Sherbrooke, Quebec, Canada Recruiting

Study contacts

• Principal investigator: Gilles Boire, MD, MSc — Centre de recherche du Centre hospitalier universitaire de Sherbrooke
• Study coordinator: Gilles Boire, MD, MSc
• Email: Gilles.Boire@USherbrooke.ca
• Phone: (819) 564-5261

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• GenAI-assisted RA bone erosion risk and DMARD choice

  This study tests whether GenAI-based decision support can help doctors assess rheumatoid arthritis bone erosion risk and pick DMARDs for newly diagnosed inpatients.

  Recruiting Guang'anmen Hospital of China Academy of Chinese Medical Sciences · Beijing, Beijing Municipality · NCT07914907

• Pain patterns in rheumatic diseases: see if pain works differently in patients and healthy people

  This observational study tests how pain is experienced and measured in people with rheumatic diseases compared with healthy volunteers.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07829497

• Telitacicept for difficult-to-treat rheumatoid arthritis

  This study tests whether adding telitacicept to standard therapy helps adults with hard-to-treat rheumatoid arthritis see better control of their symptoms.

  Recruiting Phase 2 Peking University People's Hospital · Hefei, Anhui and 46 other locations · NCT07796516

• PTC844 in people with active rheumatoid arthritis

  This study tests whether PTC844 is safe and how it behaves in the body compared with placebo for people with active rheumatoid arthritis.

  Recruiting at 6 sites Phase 2 PTC Therapeutics · Chandler, Arizona and 25 other locations · NCT07779616

• First-in-human test of CND319 in healthy people and people with rheumatic diseases

  This early study tests whether CND319 is safe and tolerable and whether it shows any signs of activity in healthy adults and in people with rheumatoid arthritis or Sjogren's syndrome.

  Recruiting Phase 1 Candid Therapeutics · Melbourne, Victoria · NCT07712939

• IV sarilumab for adults with rheumatoid arthritis

  This study tests IV sarilumab to see how it works and how safe it is for adults with moderately to severely active rheumatoid arthritis, with or without certain standard arthritis medicines.

  Recruiting at 12 sites Phase 1/2 Sanofi · Centennial, Colorado and 11 other locations · NCT07704580

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.